



**SkinBioTherapeutics plc**  
("SkinBioTherapeutics" or "the Group")

**Change of Adviser**

**22 May 2025** - SkinBioTherapeutics plc (AIM: SBTX, the Group) a life science company focused on skin health, announces that it has appointed Singer Capital Markets as its Nominated Adviser and Sole Broker with immediate effect.

**-Ends-**

**For more information please contact:**

**SkinBioTherapeutics plc**

Stuart J. Ashman, CEO  
Simon Atkinson, COO

**+44 (0) 191 495 7325**

**Singer Capital Markets**

(Nominated Adviser & Broker)  
Philip Davies  
Sam Butcher  
Patrick Weaver

**+44 (0) 20 7220 0500**

**Vigo Consulting (financial press)**

Rozi Morris

**+44 (0) 20 7390 0230**

[SkinBio@vigoconsulting.com](mailto:SkinBio@vigoconsulting.com)

**Notes to Editors**

**About SkinBioTherapeutics plc**

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: [www.skinbiotherapeutics.com](http://www.skinbiotherapeutics.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBRGDUISDDGUB